KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of April 14, 2026, KNSA stock price declined to $46.92 with 671,847 million shares trading.

KNSA has a beta of 0.23, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.00 to the broad based SPY ETF.

KNSA has a market cap of $3.56 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $202 million in Revenue and $.17 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.18.

In the last 3 years, KNSA traded as high as $50.03 and as low as $10.65.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): VTI, VB, VBK, DFAS, DFMC.

KNSA has outperformed the market in the last year with a return of +126.8%, while the SPY ETF gained +30.2%. In the last 3 month period, KNSA beat the market returning +18.6%, while SPY returned +0.9%. However, in the most recent 2 weeks KNSA has underperformed the stock market by returning -2.6%, while SPY returned +6.8%.

KNSA support price is $46.01 and resistance is $48.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.